Longeveron Inc. (LGVN)
1.63
0.02 (1.24%)
At close: Apr 24, 2025, 12:12 PM
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.
The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.
It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
The company was incorporated in 2014 and is based in Miami, Florida.
Longeveron Inc.
| Country | United States |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Mohamed Wa'el Ahmed Hashad M.B.A. |
Contact Details
Address: 1951 NW 7th Avenue Miami, Florida United States | |
| Website | https://www.longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mohamed Wa'el Ahmed Hashad M.B.A. | Chief Executive Officer & Director |
| Devin Blass | Chief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls |
| Lisa A. Locklear M.B.A. | Chief Financial Officer, Executive Vice President & Treasurer |
| Brian G Rash Ph.D. | Vice President of Research & Discovery |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Heather Zhou | Vice President & Corporate Controller |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Paul T. Lehr J.D. | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | 3 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Mar 28, 2025 | S-3 | Filing |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 4 | Filing |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 10-K | Annual Report |